{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:01:36Z","timestamp":1789095696966,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T00:00:00Z","timestamp":1487116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000266","name":"EPSRC","doi-asserted-by":"publisher","award":["1367109"],"award-info":[{"award-number":["1367109"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000275","name":"Leverhulme Trust","doi-asserted-by":"publisher","award":["ECF\/2015-075"],"award-info":[{"award-number":["ECF\/2015-075"]}],"id":[{"id":"10.13039\/501100000275","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology","award":["CE140100036"],"award-info":[{"award-number":["CE140100036"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jconrel.2017.02.005","type":"journal-article","created":{"date-parts":[[2017,2,5]],"date-time":"2017-02-05T10:16:35Z","timestamp":1486289795000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["A traceless reversible polymeric colistin prodrug to combat multidrug-resistant (MDR) gram-negative bacteria"],"prefix":"10.1016","volume":"259","author":[{"given":"Chongyu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena K.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Kempe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Velkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Haddleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2017.02.005_bb0005","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrmicro2319","article-title":"Antibiotic resistance and its cost: is it possible to reverse resistance?","volume":"8","author":"Andersson","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0010","series-title":"Anitibiotic Resistance Threats in the United States","volume":"2013","author":"U.S. Department of Health and Human Services","year":"2013"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0015","author":"O'Neill"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0020","author":"Australian Government"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0025","author":"O'Neill"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0030","first-page":"25","article-title":"Antibiotics and bacterial resistance in the 21st century","volume":"6","author":"Fair","year":"2014","journal-title":"Perspect. Med. Chem."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0035","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","article-title":"Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing","volume":"30","author":"Lim","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0040","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","article-title":"Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections","volume":"6","author":"Li","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0045","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/QCO.0b013e328332e672","article-title":"Colistin in the 21st century","volume":"22","author":"Nation","year":"2009","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijantimicag.2004.10.001","article-title":"Evaluation of colistin as an agent against multi-resistant gram-negative bacteria","volume":"25","author":"Li","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0055","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsinfecdis.5b00085","article-title":"Antimicrobial activity and toxicity of the major lipopeptide components of polymyxin B and colistin: last-line antibiotics against multidrug-resistant gram-negative bacteria","volume":"1","author":"Roberts","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0060","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1021\/jm900999h","article-title":"Structure \u2013 activity relationships of polymyxin antibiotics","volume":"53","author":"Velkov","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0065","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2217\/fmb.13.39","article-title":"Pharmacology of polymyxins: new insights into an'old'class of antibiotics","volume":"8","author":"Velkov","year":"2013","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0070","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1021\/jp064757+","article-title":"Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides","volume":"111","author":"Clausell","year":"2007","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0075","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bcp.2012.05.004","article-title":"Structure\u2013activity relationships for the binding of polymyxins with human \u03b1-1-acid glycoprotein","volume":"84","author":"Azad","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0080","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1128\/AAC.00808-15","article-title":"Mucin binding reduces colistin antimicrobial activity","volume":"59","author":"Huang","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2110-5820-1-14","article-title":"Renal and neurological side effects of colistin in critically ill patients","volume":"1","author":"Spapen","year":"2011","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0090","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3390\/molecules20011210","article-title":"Pro-moieties of antimicrobial peptide prodrugs","volume":"20","author":"Forde","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0095","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/AAC.00035-06","article-title":"Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas Aeruginosa","volume":"50","author":"Bergen","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0100","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/AAC.01741-13","article-title":"Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis","volume":"58","author":"Koomanachai","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/2110-5820-1-30","article-title":"Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients","volume":"1","author":"Michalopoulos","year":"2011","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0110","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1128\/AAC.47.4.1364-1370.2003","article-title":"Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography","volume":"47","author":"Li","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0115","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0120","doi-asserted-by":"crossref","first-page":"14323","DOI":"10.1021\/ja504390x","article-title":"Therapeutic protein\u2013polymer conjugates: advancing beyond PEGylation","volume":"136","author":"Pelegri-O'Day","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0125","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1039\/c0py90001j","article-title":"Polymer-protein conjugates: an enzymatic activity perspective","volume":"1","author":"Gauthier","year":"2010","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1146\/annurev-physchem-040412-110108","article-title":"Peptide-polymer conjugates: from fundamental science to application","volume":"64","author":"Shu","year":"2013","journal-title":"Annu. Rev. Phys. Chem."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0135","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2012.09.025","article-title":"Chemistry for peptide and protein PEGylation","volume":"64","author":"Roberts","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0140","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1021\/bm500246w","article-title":"PEG\u2013peptide conjugates","volume":"15","author":"Hamley","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0145","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1016\/S0021-9258(17)40291-2","article-title":"Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0150","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200140070-00005","article-title":"Pegylation","volume":"40","author":"Harris","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0155","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1039\/b907061c","article-title":"Synthesis and bioactivity of poly (HPMA)\u2013lysozyme conjugates: the use of novel thiazolidine-2-thione coupling chemistry","volume":"7","author":"Tao","year":"2009","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0160","doi-asserted-by":"crossref","first-page":"8474","DOI":"10.1021\/ja2120234","article-title":"Trehalose glycopolymers for stabilization of protein conjugates to environmental stressors","volume":"134","author":"Mancini","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0165","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.progpolymsci.2005.09.004","article-title":"Polymer\u2013drug conjugates: progress in polymeric prodrugs","volume":"31","author":"Khandare","year":"2006","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0170","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1021\/bc025652m","article-title":"Controlled release of proteins from their poly (ethylene glycol) conjugates: drug delivery systems employing 1, 6-elimination","volume":"14","author":"Greenwald","year":"2003","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0175","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.1021\/ja405261u","article-title":"Tunable thioesters as \u201creduction\u201d responsive functionality for traceless reversible protein PEGylation","volume":"135","author":"Chen","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0180","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1021\/bc050270c","article-title":"Linear and branched bicin linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono-and multi-PEGylated proteins","volume":"17","author":"Zhao","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0185","article-title":"Bio-reversible polyPEGylation","volume":"6560-6562","author":"Tao","year":"2009","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0190","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0169-409X(02)00179-5","article-title":"Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities","volume":"55","author":"Saito","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0195","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1021\/acs.biomac.5b01289","article-title":"pH-reversible cationic RNase A conjugates for enhanced cellular delivery and tumor cell killing","volume":"17","author":"Liu","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0168-3659(89)90025-4","article-title":"Preparation, physico-chemical and pharmacokinetic characterization of monomethoxypoly (ethylene glycol)-derivatized superoxide dismutase","volume":"10","author":"Veronese","year":"1989","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0205","series-title":"Disk Diffusion Method for Antimicrobial Susceptibility Testing, Version 5.0 (January 2015)","year":"2015"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0210","series-title":"Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement (M100-S20)","author":"CLSI","year":"2010"},{"key":"10.1016\/j.jconrel.2017.02.005_bb0215","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsinfecdis.5b00085","article-title":"Antimicrobial activity and toxicity of the major lipopeptide components of polymyxin B and colistin: last-line antibiotics against multidrug-resistant gram-negative bacteria","volume":"1","author":"Roberts","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0220","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1128\/CMR.00006-08","article-title":"Polymyxins revisited","volume":"21","author":"Landman","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0225","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/599225","article-title":"Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center","volume":"48","author":"Hartzell","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0230","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jinf.2012.01.015","article-title":"Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy","volume":"65","author":"Kubin","year":"2012","journal-title":"J. Infect."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0235","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/cid\/cit453","article-title":"Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center","volume":"57","author":"Akajagbor","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0240","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/jac\/dku561","article-title":"Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study","volume":"70","author":"Rigatto","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0245","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1093\/jac\/dkq226","article-title":"fAUC\/MIC is the most predictive pharmacokinetic\/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models","volume":"65","author":"Dudhani","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2017.02.005_bb0250","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917300585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917300585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T15:04:00Z","timestamp":1658588640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365917300585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":50,"alternative-id":["S0168365917300585"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.02.005","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A traceless reversible polymeric colistin prodrug to combat multidrug-resistant (MDR) gram-negative bacteria","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}